In the landscape of modern drug discovery, the traditional paradigm of preclinical testing is undergoing a profound metamorphosis. For decades, the workflow for toxicology studies has been linear and resource-intensive: animals are dosed, tissues are collected, slides are stained and reviewed, and the glass slides—along with the tissue blocks they were derived from—are relegated to long-term storage, often never to be touched again.
However, the rapid maturation of digital pathology is transforming these archives from "dead storage" into a vibrant, untapped goldmine of biological data. By digitizing slides and applying advanced machine learning, researchers are now finding ways to extract deeper molecular insights, effectively enabling them to answer new questions without the need for additional animal studies.
The Paradigm Shift: From Glass to Pixels
The transition to digital pathology was accelerated by necessity during the global pandemic, when remote work became an imperative for the scientific community. What began as a stopgap measure for pathologists unable to access physical microscopes has evolved into a cornerstone of data-driven research.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is essentially a collection of pixels waiting to be mined."
By pairing high-resolution digital images with historical pathology reports and molecular measurements, researchers can train sophisticated AI models to recognize patterns that correlate with specific biological responses. A single slide, once viewed only for surface-level morphology, now serves as a multifaceted data point that can be interrogated for various diagnostic and predictive purposes long after the original study has concluded.
Chronology: The Road to Modernization
The trajectory of this movement is rooted in a broader regulatory and technological timeline:
- Pre-2020: Digital pathology is primarily a niche interest, with manual microscopy serving as the gold standard for preclinical safety assessment.
- 2020–2022: The pandemic mandates remote workflows, forcing rapid adoption of whole-slide imaging. Concurrently, the industry begins to realize the data-rich potential of these digital assets.
- 2022: The enactment of the FDA Modernization Act 2.0 marks a legislative turning point, officially allowing for the use of non-animal testing methods to support investigational new drug (IND) applications.
- April 2024: Charles River Laboratories launches its Alternative Methods Advancement Project, signaling a major industry commitment to reducing the reliance on traditional animal models.
- April 2025: The FDA releases a landmark roadmap aimed at reducing animal testing in preclinical safety studies, specifically targeting monoclonal antibodies as the initial phase of a broader transition.
- September 2026: Further regulatory updates from the FDA reinforce the push toward New Approach Methodologies (NAMs), cementing the goal of making animal studies the exception rather than the rule within the next three to five years.
Virtual Controls and the Efficiency of Data
One of the most immediate impacts of this digitization is the implementation of "virtual control groups." In standard toxicology, a significant number of animals are dedicated solely to serve as a control baseline for each experimental group.
By leveraging vast repositories of historical data—ensuring that the experimental conditions and animal backgrounds are strictly comparable—researchers can effectively replace some concurrent control animals with virtual counterparts.
"Control animals represent a large fraction of every study," Dr. Zuraw notes. "By generating enough matched data to provide virtual controls wherever possible, we can significantly reduce animal numbers through simple arithmetic and rigorous statistical modeling."
The challenge, however, lies in validation. To ensure that the baseline is reliable, researchers must prove that the historical data matches the current study’s parameters perfectly. If the variance between studies is not properly accounted for, it could lead to erroneous conclusions regarding drug toxicity. Consequently, organizations like Charles River are currently focused on building robust, high-fidelity databases that provide the necessary "precedent" to satisfy regulatory bodies.
Unlocking the FFPE Archive
Beyond images, the physical archives—specifically formalin-fixed, paraffin-embedded (FFPE) blocks—are being re-evaluated as critical assets. These blocks contain the molecular history of how an animal’s tissue responded to a specific treatment.
Historically, if a researcher identified a new question after a study had concluded, the lack of fresh-frozen tissue often necessitated a repeat of the entire experiment. Now, with advancements in molecular techniques and the 2025 OECD guidance on omics analysis, researchers can perform sophisticated investigations—including gene expression and protein analysis—on archived FFPE tissue.
"You now have the option to use FFPE material that was already part of a study to gain additional information," says Dr. Zuraw. "You don’t lose the context of the study. You can extract more from the same animals and the same blocks without running a new experiment."
Technological Frontiers: Virtual Staining
As the infrastructure for digital pathology improves, more experimental methods are emerging. One of the most promising is "virtual staining." By scanning unstained tissue sections and using software to digitally generate the appearance of a stain, researchers can potentially bypass the costly and time-consuming physical staining process entirely.
While currently in the early stages of adoption, the proliferation of virtual staining applications—across diverse tissue types—suggests a future where the physical limitations of the laboratory are stripped away. Dr. Zuraw views this as a "snowball effect." As labs invest in the digital systems necessary for remote work and archive management, the barrier to entry for these cutting-edge AI-driven methodologies continues to lower.
Implications for the Future of Drug Discovery
The move toward NAMs (New Approach Methodologies) is not merely a technical upgrade; it is a fundamental shift in the ethics and efficiency of drug development.
Regulatory Compliance and Global Standards
The FDA’s roadmap, which aims to phase out animal testing for biologics and, eventually, new chemical entities, provides a clear regulatory incentive for pharmaceutical companies to adopt these digital tools. As Dr. Zuraw emphasizes, the transition will rely heavily on "early adopters"—those who work closely with regulators to troubleshoot these new methods and generate the necessary validation data.
Scientific Integrity and Reproducibility
By moving away from one-way, "throw-away" science, the industry is creating a more reproducible research environment. Digitized slides and molecular data stored alongside study context allow for better longitudinal analysis and meta-analyses, which can identify subtle toxicological trends that might be missed in individual, isolated studies.
The Human and Economic Impact
The implications for cost and time are significant. Animal studies are not only ethically complex but also time-consuming and expensive. By maximizing the utility of existing data, companies can shorten the development cycle for life-saving drugs while simultaneously upholding higher standards of animal welfare.
Conclusion
The "next act" of digital pathology is not just about digitizing images; it is about digitizing knowledge. By transforming archived tissue and historical control data into active, searchable assets, the scientific community is building a framework where the past informs the future. As laboratories transition from traditional, siloed methodologies to integrated digital platforms, the goal of reducing animal reliance is moving from a distant aspiration to an operational reality.
The snowball effect described by Dr. Zuraw is already in motion. Through the diligent work of early adopters and the clear guidance of regulatory bodies, the industry is proving that we do not always need to look to new animals to find the answers we need. Often, the answers have been sitting in our archives all along, waiting for the right technology to bring them to light.
About the Author
